ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for drug candidates. Use for assessing drug-likeness, PK properties, and safety risks early in drug discovery. Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability
Scanned 2/12/2026
Install to Claude Code
npx -y skills add huifer/drug-discovery-skills --skill admet-prediction --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Admet Prediction?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/huifer-admet-prediction)More formats (shields.io, HTML) on the badges page.
---
name: admet-prediction
description: |
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction
for drug candidates. Use for assessing drug-likeness, PK properties, and
safety risks early in drug discovery.
Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability
category: DMPK
tags: [admet, pk, toxicity, drug-likeness, safety]
version: 1.0.0
author: Drug Discovery Team
dependencies:
- rdkit
- admet-models
---
# ADMET Prediction Skill
Predict ADMET properties to prioritize compounds for development.
## Quick Start
```
/admet "CC1=CC=C(C=C1)CNC" --full
/pk-prediction --library compounds.sdf --threshold 0.7
/toxicity-screen CHEMBL210 --include hERG,DILI,Ames
```
## What's Included
| Property | Prediction | Model |
|----------|------------|-------|
| Absorption | Caco-2, HIA, Pgp | ML/QSAR |
| Distribution | VDss, PPB, BBB | ML/QSAR |
| Metabolism | CYP inhibition, clearance | ML/QSAR |
| Excretion | Clearance, half-life | ML/QSAR |
| Toxicity | hERG, DILI, Ames, mutagenicity | ML/QSAR |
## Output Structure
```markdown
# ADMET Profile: CHEMBL210 (Osimertinib)
## Summary
| Property | Value | Status |
|----------|-------|--------|
| Drug-likeness | Pass | ✓ |
| Lipinski Ro5 | 0 violations | ✓ |
| VEBER | Pass | ✓ |
| PAINS | 0 alerts | ✓ |
| Brenk | 0 alerts | ✓ |
## Absorption
| Property | Prediction | Confidence |
|----------|------------|-------------|
| HIA | 98% | High |
| Caco-2 | 15.2 × 10⁻⁶ cm/s | High |
| Pgp substrate | Yes | Medium |
| F30% | 65% | Medium |
## Distribution
| Property | Prediction | Confidence |
|----------|------------|-------------|
| VDss | 5.2 L/kg | Medium |
| PPB | 95% | High |
| BBB | Yes | High |
| CNS MPO | 5.5 | Good |
## Metabolism
| Property | Prediction | Confidence |
|----------|------------|-------------|
| CYP3A4 substrate | Yes | High |
| CYP3A4 inhibitor | Yes | Medium |
| CYP2D6 inhibitor | No | High |
| CYP2C9 inhibitor | No | Medium |
| Clearance | 8.5 mL/min/kg | Low |
## Excretion
| Property | Prediction | Confidence |
|----------|------------|-------------|
| Renal clearance | 10% | Medium |
| Half-life | 48 hours | High |
## Toxicity
| Property | Prediction | Confidence |
|----------|------------|-------------|
| hERG inhibition | No | High |
| DILI | Concern | Medium |
| Ames mutagenicity | Negative | High |
| Carcinogenicity | Negative | Medium |
| Respiratory toxicity | No | Low |
## Recommendations
**Strengths**:
- Good oral bioavailability (65%)
- Brain penetration (BBB permeable)
- Low hERG risk
**Concerns**:
- DILI concern - monitor in preclinical studies
- CYP3A4 inhibition - potential DDIs
**Overall**: Good ADMET profile. Progress to in vivo PK.
```
## Property Ranges
### Drug-Likeness
| Rule | Pass Criteria |
|------|---------------|
| Lipinski Ro5 | ≤ 1 violation |
| Veber | RotB ≤ 10, PSA ≤ 140 Ų |
| Egan | LogP ≤ 5, PSA ≤ 131 Ų |
| MDDR | MW ≤ 600, LogP ≤ 5 |
### Absorption
| Property | Good | Moderate | Poor |
|----------|------|----------|------|
| HIA | >80% | 40-80% | <40% |
| Caco-2 | >10 | 1-10 | <1 |
| F30% | >70% | 30-70% | <30% |
### Distribution
| Property | Good | Moderate | Poor |
|----------|------|----------|------|
| VDss | 0.3-5 L/kg | <0.3 or >5 | Extreme |
| PPB | <90% | 90-95% | >95% |
| BBB | LogBB > 0.3 | -0.3 to 0.3 | < -0.3 |
### Toxicity Alerts
| Alert | Action |
|-------|--------|
| hERG inhibition | Cardiotoxicity risk |
| DILI positive | Hepatotoxicity risk |
| Ames positive | Mutagenicity risk |
| PAINS | Assay interference |
| Structural alerts | Investigate further |
## Running Scripts
```bash
# Full ADMET profile
python scripts/admet_predict.py --smiles "CC1=CC=C..." --full
# Batch prediction
python scripts/admet_predict.py --library compounds.sdf --output results.csv
# Specific properties
python scripts/admet_predict.py --smiles "..." --properties hERG,DILI,CYP
# Filter by criteria
python scripts/admet_filter.py --library compounds.sdf --rules lipinski,veber
```
## Requirements
```bash
pip install rdkit
# Optional for advanced models
pip install deepchem admet-x
```
## Reference
- [reference/admet-properties.md](reference/admet-properties.md) - Detailed property reference
- [reference/toxicity-alerts.md](reference/toxicity-alerts.md) - Toxicity alerts reference
- [reference/pk-models.md](reference/pk-models.md) - PK prediction models
## Best Practices
1. **Use multiple models**: Consensus predictions more reliable
2. **Check confidence**: Low confidence = experimental verification needed
3. **Consider chemistry**: Novel structures less reliable
4. **Iterative design**: Use predictions to guide synthesis
5. **Validate early**: Confirm key predictions experimentally
## Common Pitfalls
| Pitfall | Solution |
|---------|----------|
| Over-reliance on predictions | Experimental validation required |
| Ignoring confidence | Check model applicability domain |
| Single model only | Use consensus of multiple models |
| Ignoring chemistry | Novel scaffolds = uncertain predictions |
| Late-stage testing | Early ADMET screening saves time |
## Limitations
- **Models are approximate**: Errors common
- **Novel chemistry**: Less reliable for new scaffolds
- **In vitro-in vivo gap**: Predictions don't always translate
- **Species differences**: Human predictions based on animal data
- **Complex mechanisms**: Some toxicity not predicted
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!